Federal Register / Vol. 89, No. 243 / Wednesday, December 18, 2024 / Notices 102927 

published by the journal, whether or not 

under a federal award (GPS 7.9.1). 

• Costs for services incurred after 

closeout of the award, even for an 

Author Accepted Manuscript subject to 

the NIH Public Access Policy, are 

unallowable because the costs of 

publications must be incurred before 

closeout (GPS 7.9.1). Note that this 

means that costs for publication may be 

charged after the period of performance 

and prior to closeout (i.e., during the 

120-day liquidation period). However, 

these costs must only be for the 

originally approved activities and must 

not be associated with any new work 

performed outside of the period of 

performance. 

Points To Consider for Authors and 

Institutions in Assessing Reasonable 

Costs 

As stated in Section 7.2 of the NIH 

GPS, a cost may be considered 

reasonable if the nature of the goods or 

services acquired or applied and the 

associated dollar amount reflect the 

action that a prudent person would have 

taken under the circumstances 

prevailing when the decision to incur 

the cost was made. NIH promotes 

reasonable publication costs to ensure 

an equitable system for publishing 

opportunities. However, establishing a 

particular threshold for what is 

reasonable may lead to inequitable 

outcomes in specific circumstances, so 

NIH is instead providing these Points to 

Consider in assessing reasonable costs 

to guide authors and institutions. While 

NIH may modify this approach in the 

future, NIH encourages researchers and 

institutions to consider, when 

determining whether costs are 

reasonable: 

• Amount of publication cost in relation 

to NIH award 

• Other works researchers may wish to 

produce during an award period 

• Professional and institutional 

priorities 

• Sustainability in terms of the library 

budget, laboratory budget, and other 

relevant budgets, if such costs were to 

be consistently paid 

• Relevance of the journal in 

communicating findings to advance 

science and/or improve health 

outcomes 

• Suitability of the journal’s target 

readership for the dissemination of 

the content 

Other Public Works for Which 

Allowable Costs May Be Requested 

This Guidance is primarily to help 

funded authors and institutions 

understand what costs are allowable 

under the NIH Public Access Policy. 

NIH acknowledges that the public 

dissemination of results from NIH 

funding does not occur only through 

peer-reviewed publications. Models for 

sharing research findings are evolving 

and allowable costs may be requested 

for publicly disseminating works 

reporting on the results of NIH funding 

that are not subject to the NIH Public 

Access Policy. 

As a reminder, the unallowable costs 

listed above continue to apply, and 

works must be made publicly available 

to qualify for costs. 

Reputable Journals and Responsible 

Conduct of Research 

In addition, NIH reiterates its 

Statement on Article Publication 

Resulting from NIH Funded Research 

https://grants.nih.gov/grants/guide/ 

notice-files/NOT-OD-18-011.html, a 

2017 NIH Guide Notice that encourages 

authors to publish papers resulting from 

NIH-funded research in reputable 

journals. Fees paid to journals that have 

characteristics described in the 

Statement may be considered 

unreasonable. 

Finally, NIH also reiterates the 

importance of maintaining integrity in 

science in its Guidance on the 

requirement for Instruction in the 

Responsible Conduct of Research 

https://grants.nih.gov/grants/guide/ 

notice-files/NOT-OD-22-055.html, 

which includes responsible authorship 

and publication. 

Dated: December 12, 2024. 

Lawrence A. Tabak, 

Principal Deputy Director, National Institutes 

of Health. 

[FR Doc. 2024–29929 Filed 12–17–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2025–1 Discovery and Development of Oral 

Small-molecule Direct-acting Antivirals 

Targeting Viruses of Pandemic Potential 

(Topic 146). 

Date: January 15, 2025. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52A, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Shilpakala Ketha, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3F52A, Rockville, MD 

20892, (301) 761–6821, shilpa.ketha@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: December 12, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–29838 Filed 12–17–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer at (240) 276–0361. 

Project: Substance Abuse Prevention 

and Treatment Block Grant Synar 

Report Format, FFY 2024–2026—(OMB 

No. 0930–0222)—Extension 

Section 1926 of the Public Health 

Service Act [42 U.S.C. 300x–26] 

stipulates that Substance Use 

Prevention, Treatment, and Recovery 

Services Block Grant (SUPTRS) funding 

agreements for alcohol and drug abuse 

programs for fiscal year 1994 and 


khammond on DSK9W7S144PROD with NOTICES